🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

UK stocks rally on rate cut hopes and AstraZeneca's drug approval

EditorPollock Mondal
Published 17/11/2023, 11:12 pm
© Reuters.
UK100
-
AZN
-
LSEG
-
FGP
-
FTMC
-

LONDON - UK stocks rebounded on Friday, with the FTSE 100 and FTSE 250 indices climbing by 1.1% and 1.3% respectively, as investor sentiment improved on the back of economic data suggesting that interest rates may have peaked. The market's optimism was underpinned by an anticipated shift in the Bank of England's monetary policy, with futures markets forecasting a significant decrease in interest rates by 2024.

Despite a decline in retail sales volumes this October, which pointed to cautious consumer spending, the broader market was buoyed by prospects of easing inflation and slower economic growth. These conditions have led investors to anticipate potential rate cuts from the current rate of 5.25%, with predictions of an approximate 80 basis points reduction by 2024.

In corporate news, London Stock Exchange Group (LON:LSEG)'s shares saw an uptick of 0.4% following its announcement of improved mid-term growth guidance and a commitment to return £1 billion to shareholders in 2024. This news came despite a slight dip of 0.7% in its share price earlier today, before the market recovery.

The pharmaceutical giant AstraZeneca (NASDAQ:AZN) also contributed to the positive market mood, as its shares increased by 1.2%. The boost followed approval from the U.S. health regulator for its Truqap drug, aimed at treating the most common type of breast cancer.

Adding to the upbeat news, transport company FirstGroup's shares reached a ten-year high after it announced a £100 million joint venture with Hitachi (OTC:HTHIY) Rail to lease electric bus batteries.

Investors are now closely monitoring these developments, particularly the strategic moves by London Stock Exchange Group and AstraZeneca, as they navigate through the changing economic landscape shaped by central bank policies and consumer behavior.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.